NervGen Pharma (NASDAQ:NGEN), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system repair, has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), gaining alignment on the design of its Phase 3 registrational study, RESTORE.
Aris Mining (NYSE:ARIS) reported record gold revenue of more than $360 million for the first quarter ended March 31, 2026, driven by rising production levels and an unprecedented surge in realized gold prices.
Artivion (NYSE:AORT), a leading cardiac and vascular surgery company, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the NEXUS™ Aortic Arch System.
Precigen (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of gene and cell therapies, has announced a significant acceleration in the commercial rollout of PAPZIMEOS™ (zopapogene imadenovec-drba), projecting first-quarter 2026 revenue to exceed $18 million.
Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel treatments for rare diseases, announced on April 7, 2026, that it has voluntarily withdrawn its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) for VIOKAT prolonged-release tablets.
MarketAxess Holdings (NASDAQ:MKTX), the operator of a leading electronic trading platform for fixed-income securities, reported record total credit average daily volume (ADV) for both March 2026 and the first quarter ended March 31, 2026, driven by a surge in portfolio and block trading activity.
Bluejay Diagnostics (NASDAQ:BJDX), a medical technology firm specializing in rapid near-patient testing, announced on April 7, 2026, that it has successfully enrolled 624 patients in its pivotal SYMON-II clinical trial.
Nuvalent (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, announced on April 7, 2026, the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for neladalkib.
Ascendis Pharma (NASDAQ:ASND) has officially commenced the commercial launch of YUVIWEL® (navepegritide) in the United States, marking the availability of the first once-weekly treatment for pediatric patients with achondroplasia.
Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences, has filed new patent claims that could significantly expand the addressable market for its lead candidate, GLSI-100.
Lifezone Metals (NYSE:LZM) has announced the first successful production of platinum, palladium, and rhodium from U.S.-sourced spent automotive catalytic converters, marking a technical milestone for its proprietary Hydromet Technology.
Pony.ai (NASDAQ:PONY), a global leader in autonomous driving technology, has reached a critical milestone in its international commercialization roadmap, receiving regulatory approval on April 7, 2026, to begin "by-invite" autonomous rides in Singapore.
